Efficacy and Safety of Insulin Detemir Versus Glargine in Patients With Diabetes: A Systematic Review and Meta-Analysis Publisher Pubmed



Rezaei S¹ ; Taheri A² ; Taheri S¹ ; Kasirzadeh S³ ; Fatemi B⁴ ; Sorato MM⁴ Show Affiliations
Source: Expert Review of Clinical Pharmacology Published:2022

Abstract

Objectives: Performing an updated meta-analysis to compare the safety and efficacy of insulin glargine and insulin detemir in adults with type 1 and type 2 diabetes. Methods: Electronic databases were searched up to 18 August 2021. A random-effects model was applied to pool data from included studies to calculate the standardized mean differences (SMDs) for the continuous variables and relative risks (RRs) for the dichotomous variable. Results: Nine studies compared insulin detemir and insulin glargine in type 2 diabetes and three studies in patients with type 1 diabetes. The pooled SMD of weight gain was -0.59 (95% CI -1.05 to -0.14; P=0.01; I2=98%) in patients with type 2 diabetes. The pooled RR of severe hypoglycemia was 0.28 (95% CI 0.12 to 0.63; P=0.002; I2=0%) in patients with type 1 diabetes. The effects of detemir and glargine on HbA1c, fasting plasma glucose, nocturnal hypoglycemia, and overall hypoglycemia were not statistically different (P>0.05).         Conclusions: It was found that there is no clinically considerable difference between the impacts of insulin detemir and insulin glargine in diabetic patients. The only statistically significant differences were less weight gain in type 2 diabetes and fewer episodes of severe hypoglycemia in type 1 diabetes with insulin detemir. © 2022 Informa UK Limited, trading as Taylor & Francis Group.